ZBH vs. GSK
ZBH (Zimmer Biomet Holdings, Inc.) and GSK (GlaxoSmithKline plc) are both stocks. Both are in the Healthcare sector — ZBH in Medical Devices, GSK in Drug Manufacturers - General. Over the past 10 years, ZBH returned -1.64%/yr vs 5.35%/yr for GSK. At a 0.31 correlation, their price movements are largely independent.
Performance
ZBH vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ZBH achieves a -1.23% return, which is significantly lower than GSK's 9.89% return. Over the past 10 years, ZBH has underperformed GSK with an annualized return of -1.64%, while GSK has yielded a comparatively higher 5.35% annualized return.
ZBH
- 1D
- 1.64%
- 1M
- 7.16%
- YTD
- -1.23%
- 6M
- -2.78%
- 1Y
- -1.95%
- 3Y*
- -12.72%
- 5Y*
- -9.68%
- 10Y*
- -1.64%
GSK
- 1D
- 0.34%
- 1M
- 6.78%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 34.50%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
ZBH vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ZBH Zimmer Biomet Holdings, Inc. | -1.23% | -14.03% | -12.46% | -3.81% | 4.24% | -17.02% | 3.77% | 45.37% | -13.30% | 17.86% |
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between ZBH and GSK is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Jul 25, 2001 | 0.31 |
Fundamentals
ZBH:
$17.34B
GSK:
$108.04B
ZBH:
$3.85
GSK:
£2.85
ZBH:
23.01
GSK:
13.90
ZBH:
0.34
GSK:
0.93
ZBH:
2.08
GSK:
2.47
ZBH:
1.18
GSK:
3.42
ZBH:
$8.41B
GSK:
£32.78B
ZBH:
$5.89B
GSK:
£23.87B
ZBH:
$2.21B
GSK:
£11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ZBH vs. GSK — Risk / Return Rank
ZBH
GSK
ZBH vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Zimmer Biomet Holdings, Inc. (ZBH) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZBH | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.22 | ||
| Sortino ratioReturn per unit of downside risk | -1.63 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.20 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | -0.16 | 1.58 | -1.74 |
| Martin ratioReturn relative to average drawdown | -0.31 | 3.92 | -4.23 |
Loading charts...
Drawdowns
ZBH vs. GSK - Drawdown Comparison
The maximum ZBH drawdown since its inception was -65.03%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for ZBH and GSK.
Loading charts...
Drawdown Indicators
| ZBH | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -65.03% | -55.70% | -9.33% |
Max Drawdown (1Y)Largest decline over 1 year | -25.54% | -18.63% | -6.91% |
Max Drawdown (3Y)Largest decline over 3 years | -43.94% | -28.46% | -15.48% |
Max Drawdown (5Y)Largest decline over 5 years | -48.62% | -50.10% | +1.48% |
Max Drawdown (10Y)Largest decline over 10 years | -52.14% | -50.10% | -2.04% |
Current DrawdownCurrent decline from peak | -46.73% | -11.92% | -34.81% |
Average DrawdownAverage peak-to-trough decline | -20.08% | -18.87% | -1.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.04% | 8.28% | +4.76% |
Volatility
ZBH vs. GSK - Volatility Comparison
The current volatility for Zimmer Biomet Holdings, Inc. (ZBH) is 5.90%, while GlaxoSmithKline plc (GSK) has a volatility of 6.81%. This indicates that ZBH experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ZBH | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.90% | 6.81% | -0.91% |
Volatility (6M)Calculated over the trailing 6-month period | 20.40% | 18.49% | +1.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.57% | 27.06% | +3.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 26.65% | 25.08% | +1.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 28.45% | 22.89% | +5.56% |
Dividends
ZBH vs. GSK - Dividend Comparison
ZBH's dividend yield for the trailing twelve months is around 1.08%, less than GSK's 3.26% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
ZBH Zimmer Biomet Holdings, Inc. | 1.08% | 1.07% | 0.91% | 0.79% | 0.75% | 0.76% | 0.62% | 0.64% | 0.93% | 0.80% | 0.93% | 0.86% |
Financials
ZBH vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Zimmer Biomet Holdings, Inc. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ZBH vs. GSK - Profitability Comparison
ZBH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Zimmer Biomet Holdings, Inc. reported a gross profit of 1.51B and revenue of 2.09B. Therefore, the gross margin over that period was 72.4%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
ZBH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Zimmer Biomet Holdings, Inc. reported an operating income of 373.20M and revenue of 2.09B, resulting in an operating margin of 17.9%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
ZBH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Zimmer Biomet Holdings, Inc. reported a net income of 238.10M and revenue of 2.09B, resulting in a net margin of 11.4%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
ZBH and GSK have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (6.81%) compared to ZBH (5.90%). In terms of maximum drawdown, ZBH dropped -65.03% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.09 vs -0.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ZBH and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer